The FDA has approved three versions of semaglutide, indicating that it is safe for many patients requiring treatment for one or both conditions
Hanai T, Shiraki M, Imai K, Suetugu A, Takai K, Shimizu M
Semaglutide also has a longer half-life than the older GLP-1s and may have a stronger effect on receptors in the brain, which could help explain the difference in findings, Moreno adds
Moreover, when mice were pre-treated with vehicle or L2-Cmu (20 mg/kg) by intraperitoneal (i.p.) injection, and then challenged with an intravenous (i.v.) bolus of saline or 5 g IGF-1, L2-Cmu was able to modulate IGF-1R activation in vivo, as demonstrated by a near complete inhibition of IGF-1R phosphorylation in lung and ~70% inhibition in heart (Fig